Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Dividend stocks have been a reliable cornerstone for those who want to anchor their portfolios when markets get shaky. These ...

President Trump announced certain goods exempt from reciprocal tariffs, including semiconductors, lumber, copper, and ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

At the helm of Denmark’s economic success is Novo Nordisk, the pharma company that makes Ozempic and Wegovy, blockbuster ...

Global markets and businesses were thrown into disarray by U.S. President Donald Trump’s tariff announcements on Thursday.

Here's everything you need to know about the new weight loss medication being rolled out by the NHS to treat obesity.

Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00.